CLINICAL STUDIES
Overcoming thrombolytic resistance
Rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction
Christopher P. Cannon, MDa
a Cardiovascular Division, Brigham and Womens Hospital and Harvard Medical School, Boston, Massachusetts, USA
Manuscript received January 4, 1999;
revised manuscript received May 27, 1999,
accepted June 30, 1999.
Reprint requests and correspondence: Dr. Christopher P. Cannon, Cardiovascular Division, Brigham and Womens Hospital, 75 Francis Street, Boston, Massachusetts 02115 ccannon{at}rics.bwh.harvard.edu
OBJECTIVES
We sought to review the emerging data and the clinical rationale for combining glycoprotein (GP) IIb/IIIa inhibitors with thrombolytic therapy for acute myocardial infarction (AMI).
BACKGROUND
Although thrombolytic therapy has been a major advance in the treatment of acute ST segment elevation MI, new single-bolus thrombolytic agents have been unable to break the "thrombolytic ceiling" in infarct-related artery (IRA) patency.
METHODS
Recent literature on GPIIb/IIIa inhibitors in acute coronary syndromes was reviewed.
RESULTS
A new approach toward improving current thrombolyticantithrombotic regimens focuses on "targeted therapy" for each component of the occlusive coronary thrombus: fibrin, thrombin and platelets. For the fibrin component, front-loading and/or bolus dosing of plasminogen activators (PAs) has identified the currently available doses of tissue-type plasminogen activator (t-PA) and recombinant tissue-type plasminogen activator (r-PA). For the thrombin component, several recent trials have shown that lower doses of heparin improve the safety profile of the thrombolytic-antithrombotic regimen. For the platelet component, aspirin has been shown to be effective, but the GPIIb/IIIa inhibitors offer the potential for more effective platelet inhibition and improved clinical efficacy. The benefits of GPIIb/IIIa inhibition in reducing death, MI or urgent revascularization in the setting of percutaneous coronary intervention are well established. Emerging experimental and clinical data now suggest that combining GPIIb/IIIa inhibition with reduced-dose thrombolytic therapy may improve early IRA patency without increasing bleeding risk.
CONCLUSIONS
Given the strong clinical and physiologic rationale, clinical investigation in acute ST segment elevation MI is currently focused on combining the potent GPIIb/IIIa receptor inhibitors with reduced-dose fibrinolytic agents in acute MI, with the goal of overcoming "thrombolytic resistance."
|
Abbreviations and Acronyms
| | AMI | = acute myocardial infarction | | GP | = glycoprotein | | GUSTO | = Global Utilization of Streptokinase and TPA for Occluded arteries | | ICH | = intracranial hemorrhage | | IRA | = infarct-related artery | | MI | = myocardial infarction | | PAI-1 | = plasminogen activator inhibitor-1 | | PCI | = percutaneous coronary intervention | | r-PA | = recombinant plasminogen activator | | TIMI | = Thrombolysis In Myocardial Infarction | | TNK-tpa | = TNKtissue-type plasminogen activator | | t-PA | = tissue-type plasminogen activator | | TxA2 | = thromboxane A2 |
|
This article has been cited by other articles:

|
 |

|
 |
 
S. Savonitto, P.W. Armstrong, A.M. Lincoff, G. Jia, C.A. Sila, J. Booth, P. Terrosu, C. Cavallini, H.D. White, D. Ardissino, et al.
Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction: Dichotomous response as a function of age in the GUSTO V trial
Eur. Heart J.,
October 2, 2003;
24(20):
1807 - 1814.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Topaz, E. C. Perin, R. L. Jesse, P. K. Mohanty, M. Carr, and U. Rosenschein
Power Thrombectomy in Acute Ischemic Coronary Syndromes
Angiology,
July 1, 2003;
54(4):
457 - 468.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
J. H. Heo, S. H. Kim, K. Y. Lee, E. H. Kim, C. K. Chu, and J. M. Nam
Increase in Plasma Matrix Metalloproteinase-9 in Acute Stroke Patients With Thrombolysis Failure
Stroke,
June 1, 2003;
34
(6):
e48 - e50.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. P. Giugliano, M. T. Roe, R. A. Harrington, C. M. Gibson, U. Zeymer, F. Van de Werf, K. W. Baran, H.-P. Hobbach, L. H. Woodlief, K. L. Hannan, et al.
Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: Results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic urial
J. Am. Coll. Cardiol.,
April 16, 2003;
41(8):
1251 - 1260.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A.M. Antman, J.A. de Lemos, and E. Braunwald
Epicardial flow and myocardial reperfusion following abciximab and low-dose thrombolytic therapy for acute myocardial infarction
Eur. Heart J. Suppl.,
May 1, 2001;
3(suppl_A):
A8 - A13.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
H.C. Herrmann, R.H. Li, and E.M. Ohman
Facilitated percutaneous coronary intervention: results from the SPEED trial
Eur. Heart J. Suppl.,
May 1, 2001;
3(suppl_A):
A26 - A34.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
C.H. Davies
Revascularization for cardiogenic shock
QJM,
February 1, 2001;
94(2):
57 - 67.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A de Belder
CORONARY DISEASE: Acute myocardial infarction: failed thrombolysis
Heart,
January 1, 2001;
85(1):
104 - 112.
[Full Text]
|
 |
|

|
 |

|
 |
 
P. T. Akins, S. Schneweis, D. Tirschwell, A. Furlan, L. Wechsler, M. Gent, R. Higashida, and R. Roberts
Intra-arterial Prourokinase for Acute Ischemic Stroke
JAMA,
April 26, 2000;
283(16):
2102 - 2104.
[Full Text]
[PDF]
|
 |
|
|